GeoVax Labs announced that an abstract regarding GeoVax’s gene therapy candidate, Gedeptin, has been selected for poster presentation at the American Association for Cancer Research, AACR, and the American Head and Neck Society, AHNS, joint Head and Neck Cancer Conference, being held from July 7-8, 2023 at the Palais des congres de Montreal in Montreal, QC, Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GOVX:
- GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
- GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
- GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
- GeoVax to Participate in Upcoming Industry Meetings
- GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients